Gentian Diagnostics ASA Logo

Gentian Diagnostics ASA

Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.

GENT | OL

Overview

Corporate Details

ISIN(s):
NO0010748866
LEI:
5967007LIEEXZXHNM861
Country:
Norway
Address:
Bjørnåsveien 5, 1596 Moss
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gentian Diagnostics ASA is a global developer and manufacturer of in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for major clinical chemistry platforms, aiming to enhance diagnostic efficiency for laboratories. Its product portfolio addresses high-value biomarkers for both human and veterinary medicine, with a focus on kidney disease, cardiac disease, inflammation, and infection. By developing innovative and efficient diagnostic tests, Gentian enables laboratories to reduce costs and deliver faster, more accurate results to support better treatment decisions. The company serves the global market through a network of OEM partners, distributors, and healthcare providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-23 10:15
Regulatory News Service
Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detectio…
English 102.9 KB
2025-10-23 10:15
Regulatory News Service
Gentian Diagnostics: Study Confirms the Value of Calprotectin in Early Detectio…
English 3.2 KB
2025-10-23 08:00
Investor Presentation
Gentian Diagnostics: Third quarter 2025 report - Attachment: GDASA Q3 25 presen…
English 2.1 MB
2025-10-23 08:00
Quarterly Report
Gentian Diagnostics: Third quarter 2025 report - Attachment: GDASA Interim repo…
English 865.7 KB
2025-10-23 08:00
Earnings Release
Gentian Diagnostics: Third quarter 2025 report
English 3.2 KB
2025-10-16 09:55
Report Publication Announcement
Gentian Diagnostics: Invitation to presentation of third quarter results
English 721 bytes
2025-09-16 08:11
Investor Presentation
Gentian Diagnostics presents at the Pareto Securities Healthcare conference - A…
English 1.3 MB
2025-09-16 08:11
Report Publication Announcement
Gentian Diagnostics presents at the Pareto Securities Healthcare conference
English 683 bytes
2025-07-10 08:00
Interim Report
Gentian Diagnostics: Second quarter 2025 report - Attachment: GDASA Interim re…
English 859.1 KB
2025-07-10 08:00
Investor Presentation
Gentian Diagnostics: Second quarter 2025 report - Attachment: GDASA Q2 25 pres…
English 2.2 MB
2025-07-10 08:00
Earnings Release
Gentian Diagnostics: Second quarter 2025 report
English 2.7 KB
2025-07-03 13:22
Report Publication Announcement
Gentian Diagnostics: Invitation to presentation of second quarter results
English 721 bytes
2025-06-02 16:34
Major Shareholding Notification
Flaggemelding Gentian Diagnostics ASA
Norwegian 495 bytes
2025-05-23 09:39
Major Shareholding Notification
Disclosure of shareholding
English 986 bytes
2025-05-22 08:47
Major Shareholding Notification
Disclosure of large shareholding
English 893 bytes

Automate Your Workflow. Get a real-time feed of all Gentian Diagnostics ASA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gentian Diagnostics ASA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gentian Diagnostics ASA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.